## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.44 indicates fundamental undervaluation. Quality metrics strong (ROE 20%, ROA 13%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($466.31)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. United Therapeutics (UTHR): Revisiting Valuation After Q3 2025 Growth, Strong 2027 Guidance and Rising Institutional Interest**
- Source: Sahm | 20251205T200919 | Bullish | Relevance: 100%
- United Therapeutics (UTHR) reported strong Q3 2025 earnings with 7% revenue growth and provided ambitious 2027 guidance, attracting increased institutional interest. The company's innovative pipeline, including next-generation delivery platforms and organ manufacturing, positions it as undervalued despite a significant 250% five-year shareholder return. The article suggests that UTHR, currently trading below fair value estimates, still has momentum for growth in the resilient healthcare sector.

**2. $100 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today**
- Source: Sahm | 20251203T050324 | Bullish | Relevance: 100%
- An investment of $100 in United Therapeutics (NASDAQ: UTHR) 20 years ago would be worth $1,346.56 today, showcasing the power of compounded returns. The company has outperformed the market with an annualized return of 13.91% over two decades.

**3. Flurry of Bullish Inflows Sends United Therapeutics Higher**
- Source: FXEmpire | 20251204T050325 | Bullish | Relevance: 100%
- United Therapeutics Corporation (UTHR) has seen significant bullish inflows, with its shares up 3,603% since 2004 and 34% year-to-date. The biotechnology company, specializing in treatments for chronic conditions, reported strong Q3 fiscal 2025 revenue of $800 million and projects up to $4 billion in revenue by 2027. MoneyFlows data indicates substantial institutional buying pressure, supported by robust 3-year sales growth of 19.6% and EPS growth of 36%.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-06 | UBS | $600 | $580 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-06 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 22 ($14.70M) |
| Sells | 61 ($31.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $31M sold (61 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.2x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($31.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.9B |
| Beta | 0.86 |
| 52W Range | $266.98 - $519.99 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.2 |
| Current P/E | 18.1 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 3.0pp (needs >4.0% for momentum thesis). MRS_5 at 1.0% confirms short-term momentum alignment. AM_20 at 3.3% shows strong absolute momentum above own 20MA. Outperforming sector by 3.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.53), momentum weakening. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.95% (CS: 62) | Neutral |
| RSI_14 | 67.8 | Neutral |
| MACD Histogram | -0.53 | Bearish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.083x | Above |
| vs SMA200 | 1.399x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $489.31
- **Stop Loss:** $466.31 (4.7% risk)
- **Target:** $535.31 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 21
- **Position Value:** $10,275.51
- **Portfolio %:** 10.28%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*